A two-arm, randomised, double-blind, placebo-controlled, multicenter phase II study to evaluate safety and tolerability and to explore the neuroprotective effect of atacicept as assessed by Optical Coherence Tomography (OCT) in subjects with Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) over a 36 week treatment course Evaluate the efficacy of atacicept to preserve Retinal Nerve Fiber Layer (RNFL) thickness in Optic Neuritis (ON) as assessed by Optical Coherence Tomography (OCT).

• Country None
• organs None
• Specialty None

A Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis involving hands and/or feet, with or without pustules To evaluate the safety and efficacy of Raptiva ® against placebo to control chronic moderate to severe plaque-type psoriasis involving hands and/or feet scoring PGA (PGA - H&F) ≥3 in subjects not suit...

• Country None
• organs None
• Specialty None

Clinical trial comparing the safety and efficacy of pimasertib and dacarbazine in previously untreated patients with locally advanced or metastatic malignant cutaneous melanoma showing the so-called N-Ras mutation To compare the progression-free survival (PFS) of previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma treated with either pimasertib or dacarba...

• Country None
• organs None
• Specialty None

A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) The overall objective of this trial is to: Compare the ovarian response in ART subjects administered GONAL-f according to the CONSORT calculator versus given a standard GONAL-f dose of 150 IU per day.

• Country None
• organs None
• Specialty None

A trial to determine if safinamide can attenuate levodopa induced dyskinesia in Parkinson’s disease The primary objective of this trial is to determine the maximum reduction in Unified Dyskinesia Rating Score (UDysRS) compared to baseline across all post-baseline dose visits.

• Country None
• organs None
• Specialty None

Validation study for genetic markers for growth hormone treatment in growth hormone deficient and turner syndrome patients To confirm that at least one of the genetic markers associated to the amplitude of first year growth response to recombinant human growth hormone (r-hGH) treatment identified in PREDICT Long- Term ...

• Country None
• organs None
• Specialty None

Trial of gemcitabine with or without MSC1936369B in pancreas cancer To evaluate the anti-tumor activity of MSC1936369B combined with gemcitabine compared to gemcitabine alone as first line treatment in subjects with metastatic pancreatic adenocarcinoma. During the sa...

• Country None
• organs None
• Specialty None

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients. Estudio abierto para determinar la seguridad a largo plazo de la Safinamida en pacientes con enfermedad de Parkinson To evaluate the long-term safety and tolerability of safinamide (50-100 mg p.o., q. d.) in PD patients.

• Country None
• organs None
• Specialty None

A phase IIIB, multicentre, multinational, randomized, open-label trial to compare the efficacy and safety of ovarian stimulation with GONAL-f® day 1 to day 5 followed by Pergoveris® starting day 6 to Pergoveris® starting day 1 in women between 36 and 40 years of age undergoing assisted reproductive technique (ART) The overall objective of this trial is to generate data on the ovarian stimulation profile obtained when Pergoveris® is started either on stimulation day 1 or stimulation day 6 in ART patients between...

• Country None
• organs None
• Specialty None

Phase II Trial with Safety Run-in of MEK Inhibitor AS703026 in Subjects with Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies Safety Run-in To determine the MTD for each of the two regimens of AS703026 in subjects with advanced hematological malignancies Phase II To assess the anti-leukemic activity of two regimens of AS...

• Country None
• organs None
• Specialty None